CU24315B1 - Nuevos derivados de 5-(2- {[3-(aminometil)-3,4-dihidroisoquin0-2(1 h)il] carbonil} fenil)-1 h-pirrol-3-carboxamida como inhibidores de bcl-2 y las composiciones farmacéuticas que los contienen - Google Patents

Nuevos derivados de 5-(2- {[3-(aminometil)-3,4-dihidroisoquin0-2(1 h)il] carbonil} fenil)-1 h-pirrol-3-carboxamida como inhibidores de bcl-2 y las composiciones farmacéuticas que los contienen

Info

Publication number
CU24315B1
CU24315B1 CUP2014000081A CU20140081A CU24315B1 CU 24315 B1 CU24315 B1 CU 24315B1 CU P2014000081 A CUP2014000081 A CU P2014000081A CU 20140081 A CU20140081 A CU 20140081A CU 24315 B1 CU24315 B1 CU 24315B1
Authority
CU
Cuba
Prior art keywords
aminometil
carbonil
pirrol
bcl
carboxamide
Prior art date
Application number
CUP2014000081A
Other languages
English (en)
Spanish (es)
Other versions
CU20140081A7 (es
Inventor
I Jen Chen
James Edward Paul Davidson
Nanteuil Guillaume De
Didier Durand
Imre Fejes
Olivier Geneste
Anne Françoise Guillouzic
Jean Michel Henlin
Diguarher Thierry Le
Tiran Arnaud Le
James Brooke Murray
Miklos Nyerges
Jerome Benoît Starck
Janos Tatai
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50023639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24315(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of CU20140081A7 publication Critical patent/CU20140081A7/es
Publication of CU24315B1 publication Critical patent/CU24315B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CUP2014000081A 2013-07-23 2014-07-07 Nuevos derivados de 5-(2- {[3-(aminometil)-3,4-dihidroisoquin0-2(1 h)il] carbonil} fenil)-1 h-pirrol-3-carboxamida como inhibidores de bcl-2 y las composiciones farmacéuticas que los contienen CU24315B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357258A FR3008975A1 (fr) 2013-07-23 2013-07-23 Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
CU20140081A7 CU20140081A7 (es) 2016-02-29
CU24315B1 true CU24315B1 (es) 2018-02-08

Family

ID=50023639

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2014000081A CU24315B1 (es) 2013-07-23 2014-07-07 Nuevos derivados de 5-(2- {[3-(aminometil)-3,4-dihidroisoquin0-2(1 h)il] carbonil} fenil)-1 h-pirrol-3-carboxamida como inhibidores de bcl-2 y las composiciones farmacéuticas que los contienen

Country Status (48)

Country Link
US (7) US9108983B2 (de)
EP (1) EP2829539B1 (de)
JP (1) JP5923560B2 (de)
KR (2) KR101712111B1 (de)
CN (3) CN106674201A (de)
AR (1) AR096979A1 (de)
AU (1) AU2014203521B2 (de)
BR (1) BR102014017950B1 (de)
CA (1) CA2856505C (de)
CL (1) CL2014001853A1 (de)
CR (1) CR20140307A (de)
CU (1) CU24315B1 (de)
CY (1) CY1118756T1 (de)
DK (1) DK2829539T3 (de)
DO (1) DOP2014000154A (de)
EA (1) EA026906B1 (de)
ES (1) ES2620515T3 (de)
FR (1) FR3008975A1 (de)
GE (1) GEP201706686B (de)
GT (1) GT201400144A (de)
HK (1) HK1203506A1 (de)
HR (1) HRP20170349T1 (de)
HU (1) HUE033361T2 (de)
IL (1) IL233343A (de)
JO (1) JO3275B1 (de)
LT (1) LT2829539T (de)
MA (1) MA37206B1 (de)
MD (1) MD4575C1 (de)
ME (1) ME02635B (de)
MX (1) MX348370B (de)
MY (1) MY173259A (de)
NI (1) NI201400079A (de)
PE (2) PE20150399A1 (de)
PH (1) PH12014000179A1 (de)
PL (1) PL2829539T3 (de)
PT (1) PT2829539T (de)
RS (1) RS55838B1 (de)
RU (1) RU2607788C2 (de)
SA (1) SA114350670B1 (de)
SG (1) SG10201403750UA (de)
SI (1) SI2829539T1 (de)
SV (1) SV2014004770A (de)
TN (1) TN2014000278A1 (de)
TW (1) TWI549948B (de)
UA (1) UA115773C2 (de)
UY (1) UY35639A (de)
WO (1) WO2015011400A1 (de)
ZA (1) ZA201405323B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112019001024A2 (pt) * 2016-07-22 2019-05-14 Les Laboratoires Servier combinação de um inibidor de bcl-2 e um inibidor de mcl-1, seus usos e composições farmacêuticas
UY37342A (es) 2016-07-22 2018-01-31 Servier Lab Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3801499B1 (de) 2018-06-07 2024-02-28 Disarm Therapeutics, Inc. Inhibitoren von sarm1
UY38431A (es) * 2018-10-31 2020-05-29 Servier Lab Formulación basada en ciclodextrina de un inhibidor de bcl-2
JP2022506137A (ja) * 2018-10-31 2022-01-17 レ ラボラトワール セルヴィエ Ｂｃｌ－２阻害薬の新規な塩、関連する結晶形、その調製方法及びそれを含有する医薬組成物
MX2021006702A (es) * 2018-12-06 2021-07-07 Servier Lab Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen.
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
US12139491B2 (en) 2018-12-27 2024-11-12 Holosmedic Diketopiperazine derivatives as calcium ATPase inhibitor for enhancing anticancer activity
WO2020139044A1 (ko) * 2018-12-27 2020-07-02 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 항암 활성 증진용 약학 조성물
JP2022532335A (ja) * 2019-05-14 2022-07-14 レ ラボラトワール セルヴィエ ＧＬＹ１０１ＶＡＬ突然変異を有するＢＣＬ－２媒介性ガンの処置に使用するためのＢｃｌ－２阻害剤
WO2020236825A2 (en) 2019-05-20 2020-11-26 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
CR20230046A (es) 2020-07-31 2023-04-11 Novartis Ag Combinación de un inhibidor de bcl-2 y un agente hipometilante para tratar cánceres, usos y composiciones farmacéuticas de la misma.
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
EP4251208A1 (de) 2020-11-24 2023-10-04 Novartis AG Mcl-1-inhibitor-antikörper-wirkstoff-konjugate und verfahren zur verwendung
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
CN113129644B (zh) * 2021-03-05 2022-03-08 中国人民解放军国防科技大学 基于球面扫描线的船舶三维特征航线提取方法
CA3214107A1 (en) * 2021-03-24 2022-09-29 Les Laboratoires Servier New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds
CN115246785B (zh) * 2021-04-26 2024-03-26 年衍药业(珠海)有限公司 吡咯酰胺化合物的制备方法
WO2023129553A1 (en) * 2021-12-29 2023-07-06 Eil Therapeutics, Inc. Bcl-2 inhibitors
CN114736156B (zh) * 2022-05-18 2024-03-19 中捷四方生物科技股份有限公司 一种白叶藤碱简化衍生物的制备方法及用途
EP4525926A1 (de) 2022-05-20 2025-03-26 Novartis AG Metbcl-xl-inhibitor-antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
CA3255993A1 (en) 2022-05-20 2023-11-23 Novartis Ag BCL-XL ANTIBODY-DRUG CONJUGATES AND ASSOCIATED METHODS OF USE
CR20240553A (es) 2022-05-20 2025-05-02 Servier Lab Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos
CN115960121B (zh) * 2022-10-27 2025-09-12 南通药明康德医药科技有限公司 一种合成1-(3-氧杂丁环烷基)-1h-吡唑-4-硼酸频哪醇酯的方法
IL322700A (en) 2023-03-10 2025-10-01 Novartis Ag Antibody-drug conjugates that inhibit fennerase and methods of using them
AR134424A1 (es) * 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法
TW202539634A (zh) 2024-04-10 2025-10-16 瑞士商諾華公司 Ｐａｎｒａｓ抑制劑及其使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121432A (en) 1995-12-01 2000-09-28 Suntory Ltd Pyrrolo [3,2-C]azepine-4-one derivatives and pyrrolo [3,4-C]azepine-4-one derivatives their preparation and pharmaceutical compositions containing them
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
AU2005277223C1 (en) * 2004-08-20 2009-05-21 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
US7511056B2 (en) 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
WO2006087309A1 (en) 2005-02-15 2006-08-24 Novo Nordisk A/S 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl esters
EP1861393A2 (de) * 2005-03-04 2007-12-05 AstraZeneca AB Pyrrolderivate als dna-gyrase- und topoisomeraseinhibitoren
BRPI0714346A2 (pt) 2006-07-14 2013-03-19 Genelabs Tech Inc agentes antivirais
US7706888B2 (en) 2006-07-14 2010-04-27 Med-El Elektromedizinische Geraete Gmbh Bi-planar electrode with shunting gates
SE531110C2 (sv) 2006-07-14 2008-12-23 Vaelinge Innovation Ab Låssystem omfattande ett kombinationslås för paneler
EP2225207A2 (de) 2007-11-30 2010-09-08 Biota Scientific Management Pty. Ltd. Tetrahydroisochinoline als ppat-inhibitoren zur verwendung als antibakterielle mittel
PE20120334A1 (es) 2008-12-19 2012-04-16 Abbott Lab COMPUESTOS HETEROCICLICOS INHIBIDORES DE LAS PROTEINAS ANTI-APOPTOTICAS Bcl2
US8557612B2 (en) 2009-06-26 2013-10-15 California Institute Of Technology Method for fabricating micro and nanostructures in a material
US9346795B2 (en) * 2011-05-25 2016-05-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic Bcl inhibitors
EA201491260A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
US20140357666A1 (en) * 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
HK1203506A1 (en) 2015-10-30
KR101712111B1 (ko) 2017-03-03
SI2829539T1 (sl) 2017-04-26
BR102014017950A2 (pt) 2015-11-17
HUE033361T2 (hu) 2017-11-28
PH12014000179B1 (en) 2016-01-18
MD20140072A2 (ro) 2015-01-31
CL2014001853A1 (es) 2015-06-26
MD4575C1 (ro) 2019-01-31
GEP201706686B (en) 2017-06-26
US10265323B2 (en) 2019-04-23
HK1201529A1 (en) 2015-09-04
US20190192528A1 (en) 2019-06-27
US20150313907A1 (en) 2015-11-05
SV2014004770A (es) 2015-01-28
RS55838B1 (sr) 2017-08-31
MY173259A (en) 2020-01-09
US20210290631A1 (en) 2021-09-23
WO2015011400A1 (fr) 2015-01-29
PH12014000179A1 (en) 2016-01-18
CN104341395B (zh) 2017-07-04
CA2856505A1 (fr) 2015-01-23
CN106674201A (zh) 2017-05-17
PT2829539T (pt) 2017-01-27
AU2014203521A1 (en) 2015-02-12
ES2620515T3 (es) 2017-06-28
US9108983B2 (en) 2015-08-18
UY35639A (es) 2015-02-27
GT201400144A (es) 2015-11-24
AR096979A1 (es) 2016-02-10
PL2829539T3 (pl) 2017-08-31
IL233343A (en) 2017-06-29
ME02635B (de) 2017-06-20
US9598427B2 (en) 2017-03-21
KR20150011786A (ko) 2015-02-02
CR20140307A (es) 2014-11-17
TW201512186A (zh) 2015-04-01
TWI549948B (zh) 2016-09-21
MX2014008867A (es) 2015-05-28
EP2829539A1 (de) 2015-01-28
ZA201405323B (en) 2015-09-30
US20170202851A1 (en) 2017-07-20
CA2856505C (fr) 2017-06-27
JP5923560B2 (ja) 2016-05-24
KR20170001695A (ko) 2017-01-04
JO3275B1 (ar) 2018-09-16
PE20150399A1 (es) 2015-04-11
NI201400079A (es) 2014-10-24
US10688101B2 (en) 2020-06-23
US11058689B2 (en) 2021-07-13
NZ626623A (en) 2016-01-29
FR3008975A1 (fr) 2015-01-30
EA201400753A1 (ru) 2015-03-31
CN106674196A (zh) 2017-05-17
CU20140081A7 (es) 2016-02-29
AU2014203521B2 (en) 2018-09-27
MA37206B1 (fr) 2018-09-28
US20240245699A1 (en) 2024-07-25
JP2015028018A (ja) 2015-02-12
MD4575B1 (ro) 2018-06-30
EP2829539B1 (de) 2016-12-21
PE20190653A1 (es) 2019-05-08
RU2014130125A (ru) 2016-02-20
BR102014017950B1 (pt) 2020-05-19
US20200261464A1 (en) 2020-08-20
US20150031673A1 (en) 2015-01-29
RU2607788C2 (ru) 2017-01-10
EA026906B1 (ru) 2017-05-31
MX348370B (es) 2017-06-08
LT2829539T (lt) 2017-02-27
DOP2014000154A (es) 2014-10-15
CY1118756T1 (el) 2017-07-12
SA114350670B1 (ar) 2016-02-09
DK2829539T3 (en) 2017-04-03
SG10201403750UA (en) 2015-02-27
HRP20170349T1 (hr) 2017-04-21
TN2014000278A1 (fr) 2015-09-30
UA115773C2 (uk) 2017-12-26
CN104341395A (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
CU24315B1 (es) Nuevos derivados de 5-(2- {[3-(aminometil)-3,4-dihidroisoquin0-2(1 h)il] carbonil} fenil)-1 h-pirrol-3-carboxamida como inhibidores de bcl-2 y las composiciones farmacéuticas que los contienen
CR20140275A (es) Triazolopiridinas sustituidas
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2017003258A1 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
EA201401292A2 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
MX381707B (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
CU20180073A7 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20150045A (es) Inhibidores de hepatitis c
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
SV2014004771A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY34480A (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos, composiciones y métodos para controlar malezas.
DK3003038T3 (da) 2h-1,2,3-triazolderivater som inhibitorer af fibrose
DOP2016000014A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20150447A (es) Nuevos derivados de pirazol
CL2016001266A1 (es) Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
CR20150440A (es) Nuevos derivados de piridina
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
CR20150511A (es) Nuevos derivados de purina
MX2018006802A (es) Derivados de fenilo como agonistas del receptor de canabinoides 2.
UY34038A (es) Esteres aromaticos para composiciones agroquimicas.
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
CO7151504A2 (es) Metabolitos de (1r-trans)-n-[[2-(2,3-dihidro-4-benzofuranilo)ciclopropilo]metilo]propanamida